Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures

Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures

(1) Background: Blockade of the PD-1/PD-L1 pathway has revolutionized the oncology field in the last decade. However, the proportion of patients experiencing a durable response is still limited. In the current study, we performed an extensive immune monitoring in patients with stage III/IV melanoma...

Full description

Bibliographic Details
Main Authors: Annabel Meireson, Simon J. Tavernier, Sofie Van Gassen, Nora Sundahl, Annelies Demeyer, Mathieu Spaas, Vibeke Kruse, Liesbeth Ferdinande, Jo Van Dorpe, Benjamin Hennart, Delphine Allorge, Filomeen Haerynck, Karel Decaestecker, Sylvie Rottey, Yvan Saeys, Piet Ost, Lieve Brochez
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
immunotherapy
anti-PD-1
melanoma
urothelial cancer
immune monitoring
blood biomarkers
Online Access:https://www.mdpi.com/2072-6694/13/11/2630

Internet

https://www.mdpi.com/2072-6694/13/11/2630

Similar Items